Lowest Rates of Stent Thrombosis in Real-World SCAAR Registry1
* The risk of Stent thrombosis is based on the Kaplan Meier Estimate. For the Ultimaster stent only 9 stent thromboses were reported in 1156 stents. Eight of these in one hospital.
In this real-world registry1 of over 83,000 patients, the SYNERGY stent’s thin strut design and bioabsorbable polymer coating show a trend of lower definite stent thrombosis compared to the other bioabsorbable polymer and permanent polymer drug-eluting stents.
Low Event Rates after Early DAPT Discontinuation in Complex Patients2
In a retrospective, single-center analysis of 100 extremely complex patients from Belfast, Ireland, the use of the SYNERGY stent allowed for early discontinuation of DAPT, without an increase in the incidence of stent thrombosis, MI and cardiac death at 12 Months.
The SYNERGY Stent’s real-world evidence shows positive outcomes in complex groups of patients, and the option to discontinue DAPT if the need arises.